The stock price of Exact Sciences Corp. (NASDAQ: EXAS) has surged by 4.11 when compared to previous closing price of 71.33, but the company has seen a 0.71% gain in its stock price over the last five trading sessions. Business Wire reported 2024-04-08 that MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the m.
Is It Worth Investing in Exact Sciences Corp. (NASDAQ: EXAS) Right Now?
EXAS has 36-month beta value of 1.23. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for EXAS is 179.65M, and currently, short sellers hold a 3.63% ratio of that float. The average trading volume of EXAS on April 10, 2024 was 2.26M shares.
EXAS’s Market Performance
EXAS’s stock has seen a 0.71% increase for the week, with a 23.68% rise in the past month and a 5.23% gain in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are at 4.24% for Exact Sciences Corp. The simple moving average for the last 20 days is 14.26% for EXAS stock, with a simple moving average of 2.99% for the last 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with The Benchmark Company repeating the rating for EXAS by listing it as a “Buy.” The predicted price for EXAS in the upcoming period, according to The Benchmark Company is $91 based on the research report published on January 02, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $90. The rating they have provided for EXAS stocks is “Buy” according to the report published on December 14th, 2023.
Wolfe Research gave a rating of “Outperform” to EXAS, setting the target price at $95 in the report published on December 13th of the previous year.
EXAS Trading at 18.56% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.31% of loss for the given period.
Volatility was left at 4.24%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares surge +22.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.53% upper at present.
During the last 5 trading sessions, EXAS rose by +0.71%, which changed the moving average for the period of 200-days by -21.87% in comparison to the 20-day moving average, which settled at $65.67. In addition, Exact Sciences Corp. saw 0.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Baranick Brian, who sale 924 shares at the price of $79.43 back on Apr 02 ’24. After this action, Baranick Brian now owns 13,171 shares of Exact Sciences Corp., valued at $73,393 using the latest closing price.
Condella Sarah, the EVP, Human Resources of Exact Sciences Corp., sale 2,000 shares at $70.00 during a trade that took place back on Apr 01 ’24, which means that Condella Sarah is holding 71,787 shares at $140,000 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.74 for the gross margin
The net margin for Exact Sciences Corp. stands at -0.08. The total capital return value is set at -0.04. Equity return is now at value -6.60, with -3.00 for asset returns.
Based on Exact Sciences Corp. (EXAS), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is -8.39.
Currently, EBITDA for the company is -13.13 million with net debt to EBITDA at -20.93. When we switch over and look at the enterprise to sales, we see a ratio of 6.17. The receivables turnover for the company is 12.28for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.32.
Conclusion
To put it simply, Exact Sciences Corp. (EXAS) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
